Literature DB >> 25501355

Long-Term Efficacy of Methylphenidate Immediate-Release for the Treatment of Childhood ADHD.

Carlos Renato Moreira Maia1, Samuele Cortese2, Arthur Caye1, Thomas Kuhn Deakin3, Guilherme Vanoni Polanczyk4, Carísi Anne Polanczyk1, Luis Augusto Paim Rohde1.   

Abstract

OBJECTIVE: To evaluate the long-term effects of methylphenidate imediate-release (MPH-IR), and to confirm the efficacy established in previous meta-analyses of short-term studies.
METHOD: Published and unpublished studies in which participants were treated with MPH-IR for 12 weeks or more were searched. Pooled effect sizes from these studies were computed with the DerSimonian and Laird random-effect model. Meta-regression analysis was conducted to estimate covariates associated with treatment effects.
RESULTS: Seven studies were included. Pooled parents ratings for inattention and hyperactivity/impulsivity resulted in standardized mean difference (SMD) = 0.96 (95% confidence interval [CI] = [0.60, 1.32]) and SMD = 1.12 (95% CI = [0.85, 1.39]), respectively; pooled teachers ratings showed SMD = 0.98 (95% CI = [0.09, 1.86]) for inattention and SMD = 1.25 (95% CI = [0.7, 1.81]) for hyperactivity/impulsivity. No evidence of association of any covariates with treatment effect was detected in the meta-regression.
CONCLUSION: MPH-IR is efficacious for childhood ADHD for periods longer than 12 weeks.

Entities:  

Keywords:  ADHD; meta-analysis; methylphenidate; review

Mesh:

Substances:

Year:  2016        PMID: 25501355     DOI: 10.1177/1087054714559643

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  13 in total

Review 1.  New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability.

Authors:  Samuele Cortese; Giulia D'Acunto; Eric Konofal; Gabriele Masi; Benedetto Vitiello
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

2.  Assessing risk of bias in randomized controlled trials of methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Authors:  Raíssa Rodrigues-Tartari; Walter Swardfager; Giovanni A Salum; Luís A Rohde; Hugo Cogo-Moreira
Journal:  Int J Methods Psychiatr Res       Date:  2017-09-04       Impact factor: 4.035

3.  Sleep in children with attention-deficit/hyperactivity disorder (ADHD) before and after 6-month treatment with methylphenidate: a pilot study.

Authors:  Piernanda Vigliano; Giovanni Battista Galloni; Irene Bagnasco; Giuliana Delia; Alessandra Moletto; Mauro Mana; Samuele Cortese
Journal:  Eur J Pediatr       Date:  2016-01-30       Impact factor: 3.183

Review 4.  Treatment strategies for ADHD: an evidence-based guide to select optimal treatment.

Authors:  Arthur Caye; James M Swanson; David Coghill; Luis Augusto Rohde
Journal:  Mol Psychiatry       Date:  2018-06-28       Impact factor: 15.992

5.  Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.

Authors:  Raissa Carolina F Cândido; Cristiane A Menezes de Padua; Su Golder; Daniela R Junqueira
Journal:  Cochrane Database Syst Rev       Date:  2021-01-18

6.  Comorbidity of migraine with ADHD in adults.

Authors:  Thomas Folkmann Hansen; Louise K Hoeffding; Lisette Kogelman; Thilde Marie Haspang; Henrik Ullum; Erik Sørensen; Christian Erikstrup; Ole Birger Pedersen; Kaspar René Nielsen; Henrik Hjalgrim; Helene M Paarup; Thomas Werge; Kristoffer Burgdorf
Journal:  BMC Neurol       Date:  2018-10-16       Impact factor: 2.474

Review 7.  Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Authors:  Ole Jakob Storebø; Erica Ramstad; Helle B Krogh; Trine Danvad Nilausen; Maria Skoog; Mathilde Holmskov; Susanne Rosendal; Camilla Groth; Frederik L Magnusson; Carlos R Moreira-Maia; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Bente Forsbøl; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2015-11-25

Review 8.  Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Authors:  Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B Krogh; Carlos R Moreira-Maia; Frederik L Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09

9.  No Medication for My Child! A Naturalistic Study on the Treatment Preferences for and Effects of Cogmed Working Memory Training Versus Psychostimulant Medication in Clinically Referred Youth with ADHD.

Authors:  Peter Muris; Dorien Roodenrijs; Lut Kelgtermans; Sonja Sliwinski; Ulrike Berlage; Hanna Baillieux; Anne Deckers; Marieke Gunther; Bertien Paanakker; Ida Holterman
Journal:  Child Psychiatry Hum Dev       Date:  2018-12

Review 10.  Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials.

Authors:  Ole Jakob Storebø; Helle B Krogh; Erica Ramstad; Carlos R Moreira-Maia; Mathilde Holmskov; Maria Skoog; Trine Danvad Nilausen; Frederik L Magnusson; Morris Zwi; Donna Gillies; Susanne Rosendal; Camilla Groth; Kirsten Buch Rasmussen; Dorothy Gauci; Richard Kirubakaran; Bente Forsbøl; Erik Simonsen; Christian Gluud
Journal:  BMJ       Date:  2015-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.